PFE · 10-Q · 2026Q3 · Full report

Acquired In-Process R&D Expense

PFIZER INC · 2026-11-03 · Importance 34 · Surprise 42

Acquired in-process research and development expense declined $722 million in the third quarter and $579 million in the first nine months of 2026. The 2026 expense included a $650 million charge for an in-licensing and collaboration agreement with Innovent. The comparable prior-year quarter included a $1.35 billion charge related to an in-licensing agreement with 3SBio. Reported expense was $1.390 billion in the quarter and $1.401 billion year to date, compared with credits of $52 million and $41 million, respectively, in 2025.

Key facts

• Pfizer's acquired in-process R&D expenses decreased $722 million in Q3 2026 and $579 million in the first nine months of 2026, primarily reflecting a $650 million Innovent collaboration charge versus a $1.35 billion 3SBio charge in the prior-year quarter. source